



**FTSE
RUSSELL**
An LSEG Business

Further to the [FTSE Global Equity Index Series Asia Pacific ex Japan ex China Regional Index, Japan Regional Index and China Regional Index Semi-Annual Review - Amendment v4](#) notice released on **03 March 2026**:

OBI Pharma (Taiwan, B8N9QP6) will no longer be a deletion from FTSE Global Equity Index Series Small Cap Index based on updated surveillance status on cut-off date.

All other details remain unchanged. Updated notice can be accessed via below attachments.

FTSE Global Equity Index Series Asia Pacific ex Japan ex China Regional Index, Japan Regional Index and China Regional Index Semi-Annual Review - Amendment v5

04 March 2026

The Semi-Annual review of the FTSE Global Equity Index Series - Asia Pacific ex Japan ex China, Japan and China: constituent changes can be accessed via the attachments below.

The changes will be effective after the close of business on Friday, 20 March 2026 (i.e. on Monday, 23 March 2026).

Please note: Index review changes included within the attached files may be subject to revision until close of business Friday, 06 March 2026. Effective Monday, 09 March 2026, the index review changes will be considered final. Any subsequent changes will generally only be considered in exceptional circumstances, in accordance with the FTSE Russell recalculation policy and guidelines.

[GEIS_AsiaPacific_ex_Japan_ex_China_March_2026_Amendment_v3.xlsx](#)
[GEIS_China_March_2026_Amendment_v3.xlsx](#)
[GEIS_Japan_March_2026.xlsx](#)

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia	+61 (0) 2 7228 5659
Hong Kong	+852 2164 3333
Japan	+81 3 6441 1430
London	+44 (0) 20 7866 1810
New York	+1877 503 6437

Alternatively please visit our website at lseg.com/ftse-russell

[Terms of Use](#) | Copyright © 2026 FTSE Russell